A Phase 4 interventional study of Ranibizumab and Aflibercept in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 68 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 8th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 33 in phase 4, and was the 80th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 712 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 3rd largest by enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2013, is one of 18 in phase 4, and was the 29th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
Patients attended 14 scheduled study visits during 12 months.
Key Inclusion Criteria:
Key Exclusion Criteria:
1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
Drug: Ranibizumab
1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
Drug: Aflibercept
0.5 mg intravitreal injection
Also known as: Lucentis®
2 mg intravitreal injection
Also known as: Eylea®
Mean of the Absolute Values of CSRT Difference Month 3 to Month 6
The thickness of the retina was measured by Spectral Domain Optical Coherence Topography (SD-OCT). The mean of the absolute values of the CSRT difference between Month 3 and 4, Month 4 and 5, and Month 5 and 6 was calculated (ie, CSRT fluctuation). A lower average CSRT fluctuation demonstrates greater retinal stability. One eye (study eye) contributed to the analysis.
Time frame: Month 3, Month 4, Month 5, Month 6
Total Best Corrected Visual Acuity (BCVA) Score Measured in ETDRS Letters at Month 12
Visual acuity was assessed in a sitting position with refraction using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. A higher score indicates better visual acuity. ETDRS scale ranges from 0-100 letters. A score of 65 to 70 letters represents a low to moderate visual acuity
Time frame: Month 12
IREST at Month 12
Number of incorrectly read words (IREST) was assessed using International Reading Speed Texts (IResT) and measured in words per minute.
Time frame: Month 12
National Eye Institute Visual Functioning Questionnaire Composite Score (VFQ-25) at Month 12
Vision-related quality of life was assessed by the patient using the National Eye Institute Visual Function Questionnaire. The scores of 12 subscales (general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision) were added together for a total (composite) score, which ranged from 0 to 100. A higher score indicates poorer function.
Time frame: Month 12
Correlations Between CSRT Fluctuation (Month 3 to 6) and Functional Outcomes at Month 12 (Full Analysis Set)
Correlation coefficient calculated based on Pearson's correlation between each corresponding parameter and CSRT stability.
Time frame: Month 3 to Month 6, Month 12
Patients were recruited from 6 sites in Austria, 2 sites in Belgium, 2 sites in Denmark and 5 sites from France.
| Milestone | Ranibizumab | Aflibercept |
|---|---|---|
| Started | 356 | 356 |
| Full analysis set | 353 | 354 |
| Completed | 313 | 314 |
| Not completed | 43 | 42 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Lost to follow-up | 4 | 7 |
| Withdrew: Withdrawal by subject | 13 | 8 |
| Withdrew: Lack of efficacy | 13 | 10 |
| Withdrew: Adverse event | 12 | 12 |
| Withdrew: Administrative problems | 0 | 2 |
The thickness of the retina was measured by Spectral Domain Optical Coherence Topography (SD-OCT). The mean of the absolute values of the CSRT difference between Month 3 and 4, Month 4 and 5, and Month 5 and 6 was calculated (ie, CSRT fluctuation). A lower average CSRT fluctuation demonstrates greater retinal stability. One eye (study eye) contributed to the analysis.
| micrometers | Ranibizumab | Aflibercept |
|---|---|---|
| Mean of the Absolute Values of CSRT Difference Month 3 to Month 6 | 25.16 ± 2.584 | 29.28 ± 2.620 |
Visual acuity was assessed in a sitting position with refraction using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. A higher score indicates better visual acuity. ETDRS scale ranges from 0-100 letters. A score of 65 to 70 letters represents a low to moderate visual acuity
| letters | Ranibizumab | Aflibercept |
|---|---|---|
| Total Best Corrected Visual Acuity (BCVA) Score Measured in ETDRS Letters at Month 12 | 66.4 ± 18.10 | 68 ± 17.62 |
Number of incorrectly read words (IREST) was assessed using International Reading Speed Texts (IResT) and measured in words per minute.
| incorrect words per minute | Ranibizumab | Aflibercept |
|---|---|---|
| IREST at Month 12 | 5.7 ± 21.19 | 6.1 ± 21.86 |
Vision-related quality of life was assessed by the patient using the National Eye Institute Visual Function Questionnaire. The scores of 12 subscales (general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision) were added together for a total (composite) score, which ranged from 0 to 100. A higher score indicates poorer function.
| units on a scale | Ranibizumab | Aflibercept |
|---|---|---|
| National Eye Institute Visual Functioning Questionnaire Composite Score (VFQ-25) at Month 12 | 80.0 ± 14.43 | 79.1 ± 14.95 |
Correlation coefficient calculated based on Pearson's correlation between each corresponding parameter and CSRT stability.
| correlation coefficient | Ranibizumab | Aflibercept |
|---|---|---|
| Total BCVA Score | -0.2194 | 0.0155 |
| IREST reading speed (words/minute) | 0.0889 | 0.0450 |
| VFQ-25 composite score | 0.1064 | 0.0847 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | 1/356 (0.3%) | 67/356 (18.8%) | 156/356 (43.8%) |
| Aflibercept 2 mg | 3/356 (0.8%) | 74/356 (20.8%) | 156/356 (43.8%) |
| Event | Ranibizumab 0.5 mg | Aflibercept 2 mg |
|---|---|---|
| Angina pectorisCardiac disorders | 1/356 | 5/356 |
| Coronary artery diseaseCardiac disorders | 3/356 | 4/356 |
| PneumoniaInfections and infestations | 1/356 | 4/356 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/356 | 1/356 |
| Hypertensive crisisVascular disorders | 4/356 | 1/356 |
| ConstipationGastrointestinal disorders | 0/356 | 3/356 |
| ContusionInjury, poisoning and procedural complications | 1/356 | 3/356 |
| Rib fractureInjury, poisoning and procedural complications | 1/356 | 3/356 |
| DehydrationMetabolism and nutrition disorders | 0/356 | 3/356 |
| Back painMusculoskeletal and connective tissue disorders | 1/356 | 3/356 |
| Event | Ranibizumab 0.5 mg | Aflibercept 2 mg |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 43/356 | 62/356 |
| Conjunctival haemorrhageEye disorders | 41/356 | 28/356 |
| Intraocular pressure increasedInvestigations | 29/356 | 23/356 |
| Visual acuity reducedEye disorders | 19/356 | 25/356 |
| Eye painEye disorders | 24/356 | 23/356 |
| InfluenzaInfections and infestations | 22/356 | 12/356 |
| Back painMusculoskeletal and connective tissue disorders | 12/356 | 21/356 |
| HypertensionVascular disorders | 16/356 | 21/356 |
| Ocular hyperaemiaEye disorders | 20/356 | 9/356 |
| Dry eyeEye disorders | 18/356 | 11/356 |
FAS
| Age, Continuous(years) | Ranibizumab | Aflibercept | Total |
|---|---|---|---|
| Mean | 77.3 ± 7.53 | 78.0 ± 7.21 | 77.7 ± 7.38 |
| Sex: Female, Male(Participants) | Ranibizumab | Aflibercept | Total |
|---|---|---|---|
| Female | 210 | 218 | 428 |
| Male | 143 | 136 | 279 |
| Race/Ethnicity, Customized(Participants) | Ranibizumab | Aflibercept | Total |
|---|---|---|---|
| Caucasian | 350 | 352 | 702 |
| Asian | 1 | 0 | 1 |
| Other | 2 | 2 | 4 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2013 to primary completion in Nov 2016, 36 months.
Results were first posted in Mar 2019, 2 years 3 months after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 36 months is above that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab